Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P19532: Variant p.Tyr189Cys

Transcription factor E3
Gene: TFE3
Feedback?
Variant information Variant position: help 189 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Tyrosine (Y) to Cysteine (C) at position 189 (Y189C, p.Tyr189Cys). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and aromatic (Y) to medium size and polar (C) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In MRXSPF; abolished bolished interaction with small GTPases Rag (RagA/RRAGA and RagC/RRAGC). Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 189 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 575 The length of the canonical sequence.
Location on the sequence: help PAQVPREVLKVQTHLENPTR Y HLQQARRQQVKQYLSTTLGP The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         PAQVPREVLKVQTHLENPTRYHLQQARRQQVKQYLSTTLGP

Mouse                         PAQVPREVLKVQTHLENPTRYHLQQARRQQVKQYLSTTLGP

Bovine                        PAQVPREVLKVQTHLENPTRYHLQQARRQQVKQYLSTTLGP
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 575 Transcription factor E3
Modified residue 188 – 188 Asymmetric dimethylarginine
Alternative sequence 110 – 575 Missing. In isoform 2.



Literature citations
A central role for regulated protein stability in the control of TFE3 and MITF by nutrients.
Nardone C.; Palanski B.A.; Scott D.C.; Timms R.T.; Barber K.W.; Gu X.; Mao A.; Leng Y.; Watson E.V.; Schulman B.A.; Cole P.A.; Elledge S.J.;
Mol. Cell 83:57-73(2023)
Cited for: FUNCTION; SUBCELLULAR LOCATION; INTERACTION WITH SMALL GTPASES RAG; PHOSPHORYLATION AT SER-47 AND SER-321; UBIQUITINATION; MUTAGENESIS OF SER-47; SER-321 AND 356-ARG--ARG-359; VARIANTS MRXSPF GLY-184; LEU-186; MET-187; CYS-189; GLN-190; PRO-191 AND PRO-201; CHARACTERIZATION OF VARIANTS MRXSPF GLY-184; LEU-186; MET-187; CYS-189; GLN-190; PRO-191 AND PRO-201; De novo mutations in the X-linked TFE3 gene cause intellectual disability with pigmentary mosaicism and storage disorder-like features.
Lehalle D.; Vabres P.; Sorlin A.; Bierhals T.; Avila M.; Carmignac V.; Chevarin M.; Torti E.; Abe Y.; Bartolomaeus T.; Clayton-Smith J.; Cogne B.; Cusco I.; Duplomb L.; De Bont E.; Duffourd Y.; Duijkers F.; Elpeleg O.; Fattal A.; Genevieve D.; Guillen Sacoto M.J.; Guimier A.; Harris D.J.; Hempel M.; Isidor B.; Jouan T.; Kuentz P.; Koshimizu E.; Lichtenbelt K.; Loik Ramey V.; Maik M.; Miyakate S.; Murakami Y.; Pasquier L.; Pedro H.; Simone L.; Sondergaard-Schatz K.; St-Onge J.; Thevenon J.; Valenzuela I.; Abou Jamra R.; van Gassen K.; van Haelst M.M.; van Koningsbruggen S.; Verdura E.; Whelan Habela C.; Zacher P.; Riviere J.B.; Thauvin-Robinet C.; Betschinger J.; Faivre L.;
J. Med. Genet. 57:808-819(2020)
Cited for: VARIANTS MRXSPF GLN-117; GLY-184; LYS-187; MET-187; PRO-187; CYS-189; GLN-190 AND PRO-191;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.